Cytek Biosciences, INC Form 4 insider transactions

A Cytek Biosciences executive reported the vesting of Restricted Stock Units and the sale of shares to cover tax obligations.

Cytek Biosciences' Chief Legal Officer, Valerie Barnett, reported the vesting of Restricted Stock Units and subsequent share dispositions for tax obligations.

Cytek Biosciences CEO Wenbin Jiang reported future vesting of Restricted Stock Units and associated tax-related share dispositions scheduled for August 18, 2025, increasing his direct common stock ownership.

Cytek Biosciences' Chief Financial Officer, William D. McCombe, reported the vesting of Restricted Stock Units and subsequent share disposals for tax obligations.

Cytek Biosciences Director Michael Holder converted 2,181 Restricted Stock Units into common stock, increasing his direct beneficial ownership.

Cytek Biosciences Director Richard Chin reported the vesting and acquisition of 4,071 common shares from Restricted Stock Units.

Cytek Biosciences, Inc. Director Richard Chin was granted 73,289 Restricted Stock Units and options to purchase 39,062 shares of common stock on June 18, 2025, as part of his compensation.

Cytek Biosciences, Inc. Director Deborah J. Neff was granted 43,973 Restricted Stock Units and options to purchase 23,809 shares of common stock, with vesting scheduled for June 2026.

Cytek Biosciences, Inc. Director Jack Ball was granted 43,973 Restricted Stock Units and options to purchase 23,809 shares of common stock, aligning his interests with shareholders.

Cytek Biosciences, Inc. Director Michael Holder was granted 43,973 Restricted Stock Units and 23,809 stock options, aligning his interests with shareholder value.

Cytek Biosciences, Inc. Director Vera Imper was granted 43,973 Restricted Stock Units and options to purchase 23,809 shares of common stock, aligning her interests with shareholders.

Vera Imper, a Director at Cytek Biosciences, Inc., converted 15,706 Restricted Stock Units into an equal number of common shares on June 5, 2025, increasing her direct beneficial ownership.

Don M. Hardison, a Director at Cytek Biosciences, Inc., has acquired 15,706 shares of common stock following the vesting of Restricted Stock Units on June 5, 2025.

Jack Ball, a Director at Cytek Biosciences, Inc., acquired 15,706 shares of common stock through the vesting of Restricted Stock Units on June 5, 2025, increasing his direct beneficial ownership to 42,705 shares.

Deborah J. Neff, a Director at Cytek Biosciences, Inc., acquired 15,706 shares of common stock on June 5, 2025, through the vesting of Restricted Stock Units.

Cytek Biosciences' Chief Financial Officer, William D. McCombe, has acquired 35,000 shares of common stock at a weighted average price of $2.78 per share, increasing his beneficial ownership to 55,746 shares.

William D. McCombe, CFO of Cytek Biosciences, reports the vesting and subsequent tax withholding related to restricted stock units.

Wenbin Jiang, CEO of Cytek Biosciences, reports the vesting and subsequent tax withholding of restricted stock units, resulting in adjustments to his beneficial ownership of company stock.

Valerie Barnett, Chief Legal Officer of Cytek Biosciences, reports the vesting of restricted stock units and subsequent tax withholding.

Philippe Busque, SVP of Global Sales and Services at Cytek Biosciences, reports the vesting of restricted stock units and subsequent tax withholding.

Ming Yan, Chief Technology Officer of Cytek Biosciences, reports the acquisition and disposal of common stock and restricted stock units on May 19, 2025, related to vesting of RSU awards.

Director Michael Holder of Cytek Biosciences reports the acquisition and disposal of common stock and derivative securities.

Valerie Barnett, Chief Legal Officer of Cytek Biosciences, reports the vesting of restricted stock units and subsequent tax withholding.

Philippe Busque, SVP at Cytek Biosciences, reports transactions involving common stock and restricted stock units, resulting in adjustments to his beneficial ownership.

Wenbin Jiang, CEO of Cytek Biosciences, reports transactions involving restricted stock units and common stock on March 10, 2025.

Cytek Biosciences' Chief Technology Officer, Yan Ming, reports the vesting of restricted stock units and subsequent tax withholding.

Director Michael Holder reports the acquisition and disposal of Cytek Biosciences common stock and restricted stock units on March 10, 2025.

Cytek Biosciences' Chief Technology Officer, Yan Ming, reports the acquisition of stock options and restricted stock units.

William D. McCombe, CFO of Cytek Biosciences, received stock options and restricted stock units (RSUs) on March 4, 2025, according to a Form 4 filing with the SEC.

Wenbin Jiang, CEO of Cytek Biosciences, reports the acquisition of stock options and restricted stock units.